LivaNova reported adjusted EPS of $0.86 for Q4, beating the consensus estimate of $0.80 and up from $0.81 in the prior-year period. Total revenue surpassed analyst forecasts, reflecting strength across its global device portfolio.

The EPS outperformance was driven by stronger device sales and operational efficiencies across cardiovascular and neuromodulation segments. Broad-based demand and cost controls supported margin expansion during the quarter.